Common Prior Authorization Criteria BMI documentation: Most states require a documented BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea) Failed lifestyle modification: Typically 3 to 6 months of documented dietary counseling and physical activity recommendations that did not produce adequate weight loss Step therapy: Some states require patients to try and fail less expensive medications (phentermine, orlistat) before approving GLP-1 coverage Provider qualification: Some Medicaid plans require the prescriber to have completed training in obesity medicine
After that, your dose may be increased by 0.5mg every 4 weeks up to 2 mg once weekly, depending on how you respond to the medication For weight purposes, its important to follow medical advice, but generally, dosages should not exceed the maintenance dose of 2 mg once weekly, as this is considered the upper limit for safe use
Review: magnetic resonance spectroscopy studies of pediatric major depressive disorder
This broad central distribution allows GLP-1RAs to modulate additional neural pathways implicated in the motivational aspects of substance use
In weight management, delayed gastric transit and reduced appetite drive behavioral calorie restriction independent of diabetes status
Good providers customize based on your specific situation